FDA kwadoro Recarbio ka ọ gwọọ ọrịa nje oyi ịba n'ụlọ ọgwụ na ikuku na-akpata
Nlekọta ihe oriri na ọgwụ ọjọọ nke US (FDA) akwadowo Recarbrio (nchikota imipenem, cilastatin na relebactam) maka ịgwọ ọrịa nje na-efe efe na ọrịa oyi ịba ọcha na-akpata (HABP / VABP) na ndị ọrịa afọ 18 gbagoro. .
Ndị FDA kwadoro na Recarbrio na mbụ maka ọrịa urinary tract na-ebute mgbagwoju anya na ọgwụgwọ ọnya afọ. Ugbu a, FDA na-ekwupụta na ọ nwere ike ịbụ ọgwụ nje maka oyi baa.
Recarbrio, ọ nwere ike ịbụ ọgwụ nje maka ọrịa oyi na-akpata n'ụlọ ọgwụ nwere?
A na-enyocha nchekwa na arụmọrụ nke Recarbrio maka akara ndị ọzọ maka nyocha a na-enyocha ọgwụ na-enweghị usoro na 535 okenye nọ n'ụlọ ọgwụ na HABP / VABP n'ihi nje Gram-na-adịghị mma: a na-agwọ ndị ọrịa 266 Recarbrio na ndị ọrịa 269 na-enwe piperacillin-tazobactam.
Na mkpokọta, rue ubochi 28 nke ihe omumu a, 16% nke ndi ọrịa mesoro Recarbrio na 21% nke ndi ozo nwuru.
Ọgwụ nje maka nje na-efe efe: a na-ahụkarị mmeghachi omume ọjọọ
Mmeghachi omume kachasị njọ a hụrụ na ndị ọrịa lebara Recarbrio gụnyere ịba ụba aspartate / alanine aminotransferase, anaemia, afọ ọsịsa, hypokalemia na hyponatraemia.
Recarbrio natara ntupụta Ahụhụ ruru eru (QIDP) n'okpuru nchekwa FDA Safety and Innovation Act's na-ebute Mbelata Antibiotic Ugbu a (GAIN), nke ụlọ ọrụ US kwuru na ọgwụ nje na antifungals bu n’obi ịgwọ ọrịa dị egwu ma ọ bụ na-eyi ndụ egwu. Dịka akụkụ nke atụmatụ QIDP, Recarbrio akpọwo nyocha nke Mbuzọ ma nwee ya na ngwa ngwa ngwa ngwa ejikwa ya.
Ọgwụ nje maka nje na-efe efe: G ARKWU AK ITKỌ ALtali
GỤRỤ AHỤ
Pulmonary na thyroid carcinoma: FDA kwadoro ọgwụgwọ na Retevmo
COVID-19 na US: FDA nyere ikike ihe mberede ka ọ jiri Remdesivir na-agwọ ndị ọrịa coronavirus
COVID-19, Andrea Bocelli meriri coronavirus ma nye onyinye plasma hyperimmune